Immunogenicity

Scientists Overcome COVID-19 Obstacles to Continue Discovery and Innovation

Retrieved on: 
Monday, May 23, 2022

Yet within the shadow cast by the pandemic, groundbreaking discoveries continued here in the fields of genetics, developmental biology, ophthalmology, cancer biology, immunobiology and more.

Key Points: 
  • Yet within the shadow cast by the pandemic, groundbreaking discoveries continued here in the fields of genetics, developmental biology, ophthalmology, cancer biology, immunobiology and more.
  • The most significant of these innovations can be found in our 2021 Research Annual Report , published on behalf of the Cincinnati Children's Research Foundation .
  • Along the way, scientists here published more than 2,000 peer-reviewed research papers across the spectrum of conditions that never stopped affecting child health, pandemic or not.
  • Read more about how Cincinnati Children's carried on its research mission while responding in numerous ways to the COVID-19 pandemic.

AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

Retrieved on: 
Monday, May 9, 2022

LAUSANNE, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. This is the first anti-Abeta vaccine study conducted with people living with DS.

Key Points: 
  • Dr. Michael Rafii commented: The data published today in JAMA Neurology demonstrate that interventional clinical trials can be successfully conducted in individuals with Down syndrome.
  • Importantly, the ACI-24 anti-Abeta vaccine was safe, well-tolerated and an anti-Abeta immune response was observed in ACI-24-treated but not placebo-treated participants.
  • Rafii MS et al, Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome, A Phase 1b Randomized Clinical Trial, JAMA Neurology, 2022 May 9:79(5).
  • This randomized, double-blind, placebo-controlled, dose-escalation, phase 1b multi-center study reported in JAMA Neurology included 16 adults, aged 25-41 years.

Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology

Retrieved on: 
Thursday, April 21, 2022

Osivax , a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today that the Phase 2a results for its broad-spectrum influenza vaccine candidate, OVX836 , have been published under the title Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine in the journal Frontiers in Immunology.

Key Points: 
  • Osivax , a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today that the Phase 2a results for its broad-spectrum influenza vaccine candidate, OVX836 , have been published under the title Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine in the journal Frontiers in Immunology.
  • Osivax influenza vaccine, OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen.
  • OVX836 has shown promising safety, immunogenicity, and efficacy in preclinical and clinical trials (Phase 1 and Phase 2a).
  • The company is establishing proof of concept with its highly validated lead influenza candidate, OVX836, which is currently in Phase 2 testing with over 500 subjects tested.

Computational Biology Market size worth $ 12.45 Billion, Globally, by 2028 at 20.64% CAGR: Verified Market Research®

Retrieved on: 
Tuesday, March 15, 2022

According to Verified Market Research, the Global Computational Biology Market size was valued at USD 2.76 Billion in 2018 and is projected to reach USD 12.45 Billion by 2026, growing at a CAGR of 20.64 % from 2019 to 2026.

Key Points: 
  • According to Verified Market Research, the Global Computational Biology Market size was valued at USD 2.76 Billion in 2018 and is projected to reach USD 12.45 Billion by 2026, growing at a CAGR of 20.64 % from 2019 to 2026.
  • In the areas of genomics, proteomics, pharmacogenomics, and drug development, computational biology offers a wide range of applications.
  • The Computational Biology Market expansion may be limited by a severe dearth of trained professionals.
  • Verified Market Research has segmented the Global Computational Biology Market On the basis of End-User, Application, and Geography.

Computational Biology Market size worth $ 12.45 Billion, Globally, by 2028 at 20.64% CAGR: Verified Market Research®

Retrieved on: 
Tuesday, March 15, 2022

JERSEY CITY, N.J., March 15, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Computational Biology Market" By End-User (Industry, Commercial, Academics), By Application (Preclinical Drug Development, Human Body Simulation Software, Drug Discovery & Disease Modelling), and By Geography. According to Verified Market Research, the Global Computational Biology Market size was valued at USD 2.76 Billion in 2018 and is projected to reach USD 12.45 Billion by 2026, growing at a CAGR of 20.64 % from 2019 to 2026.

Key Points: 
  • JERSEY CITY, N.J., March 15, 2022 /PRNewswire/ -- Verified Market Research recently published a report, " Computational Biology Market " By End-User (Industry, Commercial, Academics), By Application (Preclinical Drug Development, Human Body Simulation Software, Drug Discovery & Disease Modelling), and By Geography.
  • According to Verified Market Research, the Global Computational Biology Market size was valued at USD 2.76 Billion in 2018 and is projected to reach USD 12.45 Billion by 2026, growing at a CAGR of 20.64 % from 2019 to 2026.
  • In the areas of genomics, proteomics, pharmacogenomics, and drug development, computational biology offers a wide range of applications.
  • Verified Market Research has segmented the Global Computational Biology Market On the basis of End-User, Application, and Geography.

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Retrieved on: 
Wednesday, February 23, 2022

SAN CARLOS, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the first participants were dosed in the Phase 1/2 clinical study of VAX-24. This clinical proof-of-concept study will evaluate the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumonia in adults. The Company expects to announce topline safety, tolerability and immunogenicity results from the Phase 1/2 study by the end of 2022.

Key Points: 
  • This clinical proof-of-concept study will evaluate the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumonia in adults.
  • The Company expects to announce topline safety, tolerability and immunogenicity results from the Phase 1/2 study by the end of 2022.
  • The VAX-24 Phase 1/2 clinical proof-of-concept study is a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults.
  • Vaxcytes lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of IPD and pneumonia.

SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations

Retrieved on: 
Tuesday, August 10, 2021

The publications detail findings from clinical studies on the immunogenicity, safety, and immune response of CoronaVac in two- and three-dose schedules.

Key Points: 
  • The publications detail findings from clinical studies on the immunogenicity, safety, and immune response of CoronaVac in two- and three-dose schedules.
  • The results indicate that a third booster dose of CoronaVac induces a strong immune response in healthy adults with no serious adverse reactions related to the vaccine.
  • This research provides important scientific data and supplement existing research to help policymakers develop strategies for vaccine rollout and timing of booster doses.
  • In addition, a third dose was found to be well-tolerated in elderly patient populations with no vaccine-related serious adverse events reported.

IASO Biotherapeutics’ World’s First Fully Human CD19/CD22 Dual-Targeted CAR-T Drug Receives Two IND Clearances, Enters Clinical Trials

Retrieved on: 
Monday, August 2, 2021

Moreover, CT120 uses fully human antibody sequences, which can reduce the anti-drug antibody (ADA) effect and improve the in vivo persistence of CAR-T cells.

Key Points: 
  • Moreover, CT120 uses fully human antibody sequences, which can reduce the anti-drug antibody (ADA) effect and improve the in vivo persistence of CAR-T cells.
  • The CD19 antibody sequence of CT120 is developed on IASO Bios fully human antibody platform IMARS and high throughput CAR-T drug selection platform.
  • The companys high-throughput CAR-T drug selection platform, which uses cutting-edge single-cell analysis and next-generation sequencing (NGS) technology, can implement cost effective, high efficiency functional CAR-T candidate screening.
  • Adopting a fully human design, CT120 has low immunogenicity, reduces the ADA effect, and improves CAR-T cells viability.

NexImmune Strengthens Management Team with Key Appointments

Retrieved on: 
Wednesday, July 14, 2021

We are excited to announce the continued expansion of our leadership team, said Scott Carmer, Chief Executive Officer of NexImmune.

Key Points: 
  • We are excited to announce the continued expansion of our leadership team, said Scott Carmer, Chief Executive Officer of NexImmune.
  • Dr. Ragheb was most recently a Senior Medical Fellow for Immunology and Co-chair of the Immunogenicity/Immunosafety Working group at Eli Lilly.
  • Im humbled and excited to join the highly accomplished team at NexImmune and look forward to contributing to the advancement of its preclinical pipeline and clinical assets, said Dr. Ragheb.
  • The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response.

Immuno-Oncology: Functional Assays for Immune Checkpoint Inhibitors as Emerging Therapeutics, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, July 12, 2021

This webinar will showcase assays to evaluate cellular pathways of immune cells, T-cells, and macrophages while highlighting functional and immunogenicity assays developed in support of current and emerging therapeutics.

Key Points: 
  • This webinar will showcase assays to evaluate cellular pathways of immune cells, T-cells, and macrophages while highlighting functional and immunogenicity assays developed in support of current and emerging therapeutics.
  • The speakers will outline how in vitro methods mimic the tumor environment to measure therapeutic functionality.
  • For more information, or to register for this event, visit Immuno-Oncology: Functional Assays for Immune Checkpoint Inhibitors as Emerging Therapeutics.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.